CARGO Therapeutics, Inc. Common Stock
NasdaqGS CRGX
CARGO Therapeutics, Inc. Common Stock Price to Sales Ratio (P/S) on February 06, 2025
-
CARGO Therapeutics, Inc. Common Stock 52-week high Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
CARGO Therapeutics, Inc. Common Stock 52-week low Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
CARGO Therapeutics, Inc. Common Stock average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Don’t Miss A Beat
| CEO | Ms. Gina Chapman |
| IPO Date | Nov. 13, 2023 |
| Location | United States |
| Headquarters | 1900 Alameda De Las Pulgas |
| Employees | 170 |
| Sector | Healthcare |
| Industries | |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Past 5 years
StockViz Staff
February 8, 2025
Any question? Send us an email